XML 28 R19.htm IDEA: XBRL DOCUMENT
v3.22.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Novartis Institutes for BioMedical Research, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Novartis agreement: |  |  |  |  |  |  |
Recognition of upfront license fee | $ | 8,622 |  |  | $ | 7,559 |  |  | $ | 15,640 |  |  | $ | 13,759 |
Research services | 2,306 |  |  | 2,022 |  |  | 4,183 |  |  | 3,683 |
Total | $ | 10,928 |  |  | $ | 9,581 |  |  | $ | 19,823 |  |  | $ | 17,442 |
Biogen MA, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Biogen agreement: |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 7,306 |  |  | $ | 7,306 |  |  | $ | 14,612 |  |  | $ | 14,612 |
Research services | 2,746 |  |  | 3,461 |  |  | 6,633 |  |  | 6,605 |
Total | $ | 10,052 |  |  | $ | 10,767 |  |  | $ | 21,245 |  |  | $ | 21,217 |
Kite Pharma, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Kite agreement: |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 6,227 |  |  | $ | 6,227 |  |  | $ | 12,386 |  |  | $ | 12,386 |
Research services | 107 |  |  | 97 |  |  | 256 |  |  | 226 |
Total | $ | 6,334 |  |  | $ | 6,324 |  |  | $ | 12,642 |  |  | $ | 12,612 |
Sanofi S.A. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Sanofi agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | 366 |  |  | $ | 206 |  |  | $ | 677 |  |  | $ | 433 |
Research services | 1,148 |  |  | 613 |  |  | 2,126 |  |  | 1,292 |
Milestone achievement | 247 |  |  | 138 |  |  | 457 |  |  | 292 |
Total | $ | 1,761 |  |  | $ | 957 |  |  | $ | 3,260 |  |  | $ | 2,017 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |